Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14 778 Patients from the French Health Insurance Database (SNDS)
RMD Open. 2023;9(4):e003570 doi: 10.1136/rmdopen-2023-003570
Nationwide study involving 14 778 new users of targeted therapies with PsA found treatment persistence to be lower for women than men for TNFi and IL17i but not for IL-12/23i, IL-23i or JAK inhibition.
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.